Cargando…
Vascular Normalization: A New Window Opened for Cancer Therapies
Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular norm...
Autores principales: | , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406857/ https://www.ncbi.nlm.nih.gov/pubmed/34476218 http://dx.doi.org/10.3389/fonc.2021.719836 |
_version_ | 1783746566278873088 |
---|---|
author | Yang, Ting Xiao, Hongqi Liu, Xiaoxia Wang, Zhihui Zhang, Qingbai Wei, Nianjin Guo, Xinggang |
author_facet | Yang, Ting Xiao, Hongqi Liu, Xiaoxia Wang, Zhihui Zhang, Qingbai Wei, Nianjin Guo, Xinggang |
author_sort | Yang, Ting |
collection | PubMed |
description | Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular normalization, has been shown not only capable of reducing tumor invasion and metastasis but also of enhancing the effectiveness of chemotherapy, radiation therapy, and immunotherapy. In addition to the introduction of such methods of promoting tumor vascular normalization such as maintaining the balance between proangiogenic and antiangiogenic factors and targeting endothelial cell metabolism, microRNAs, and the extracellular matrix, the latest molecular mechanisms and the potential connections between them were primarily explored. In particular, the immunotherapy-induced normalization of blood vessels further promotes infiltration of immune effector cells, which in turn improves immunotherapy, thus forming an enhanced loop. Thus, immunotherapy in combination with antiangiogenic agents is recommended. Finally, we introduce the imaging technologies and serum markers, which can be used to determine the window for tumor vascular normalization. |
format | Online Article Text |
id | pubmed-8406857 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-84068572021-09-01 Vascular Normalization: A New Window Opened for Cancer Therapies Yang, Ting Xiao, Hongqi Liu, Xiaoxia Wang, Zhihui Zhang, Qingbai Wei, Nianjin Guo, Xinggang Front Oncol Oncology Preclinical and clinical antiangiogenic approaches, with multiple side effects such as resistance, have not been proved to be very successful in treating tumor blood vessels which are important targets for tumor therapy. Meanwhile, restoring aberrant tumor blood vessels, known as tumor vascular normalization, has been shown not only capable of reducing tumor invasion and metastasis but also of enhancing the effectiveness of chemotherapy, radiation therapy, and immunotherapy. In addition to the introduction of such methods of promoting tumor vascular normalization such as maintaining the balance between proangiogenic and antiangiogenic factors and targeting endothelial cell metabolism, microRNAs, and the extracellular matrix, the latest molecular mechanisms and the potential connections between them were primarily explored. In particular, the immunotherapy-induced normalization of blood vessels further promotes infiltration of immune effector cells, which in turn improves immunotherapy, thus forming an enhanced loop. Thus, immunotherapy in combination with antiangiogenic agents is recommended. Finally, we introduce the imaging technologies and serum markers, which can be used to determine the window for tumor vascular normalization. Frontiers Media S.A. 2021-08-12 /pmc/articles/PMC8406857/ /pubmed/34476218 http://dx.doi.org/10.3389/fonc.2021.719836 Text en Copyright © 2021 Yang, Xiao, Liu, Wang, Zhang, Wei and Guo https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Oncology Yang, Ting Xiao, Hongqi Liu, Xiaoxia Wang, Zhihui Zhang, Qingbai Wei, Nianjin Guo, Xinggang Vascular Normalization: A New Window Opened for Cancer Therapies |
title | Vascular Normalization: A New Window Opened for Cancer Therapies |
title_full | Vascular Normalization: A New Window Opened for Cancer Therapies |
title_fullStr | Vascular Normalization: A New Window Opened for Cancer Therapies |
title_full_unstemmed | Vascular Normalization: A New Window Opened for Cancer Therapies |
title_short | Vascular Normalization: A New Window Opened for Cancer Therapies |
title_sort | vascular normalization: a new window opened for cancer therapies |
topic | Oncology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8406857/ https://www.ncbi.nlm.nih.gov/pubmed/34476218 http://dx.doi.org/10.3389/fonc.2021.719836 |
work_keys_str_mv | AT yangting vascularnormalizationanewwindowopenedforcancertherapies AT xiaohongqi vascularnormalizationanewwindowopenedforcancertherapies AT liuxiaoxia vascularnormalizationanewwindowopenedforcancertherapies AT wangzhihui vascularnormalizationanewwindowopenedforcancertherapies AT zhangqingbai vascularnormalizationanewwindowopenedforcancertherapies AT weinianjin vascularnormalizationanewwindowopenedforcancertherapies AT guoxinggang vascularnormalizationanewwindowopenedforcancertherapies |